Elastosis in breast carcinoma

Elastosis, the significant increase of elastic tissue, was identified by histochemical methods in 45 (53.5%) cases of an unselected series of breast cancers. They were all invasive ductal carcinomas with or without tubular differentiation. The highest proportion of tumors with elastosis was found in the "scirrhous" type of carcinomas. Elastosis was preponderantly of the focal variety, periductal and perivenous. The affected ducts were of large calibre, containing a normal, benign hyperplastic or carcinomatous epithelium. There were not observed correlations with the grade of malignancy and the extent of axillary lymph node metastases.     

Collagenase in carcinoma cells

Collagenolytic enzyme activity has been found in high levels in homogenates of a tumor (ascitic V₂ carcinoma) implanted in rabbit muscle. Unlike other mammalian collagenases, this enzyme was not actively synthesized and released by primary cultures of the tumor. Most of the collagenolytic activity in tumor homogenates was found to sediment at 1000–4000 × g along with 5′-nucleotidase activity indicating that it might be bound to a membraneous component of the cell.     

Detecting hepatocellular carcinoma in blood

Liquid biopsy is ideal for early diagnosis of cancer and for prognosis upon treatment. Wen et al. describe a methylated CpG tandems amplification and sequencing method to profile hypermethylated CpG islands genome-widely in cell-free DNA, and further identify high performance markers in blood for potential detection of early stage hepatocellular carcinoma.Early diagnosis is key to cancer prevention and treatment. When physiological consequences of cancer are observed it could be too late for the optimal treatment and therapy¹. Traditional biopsy has been widely used for diagnosis; however, it is difficult to frequently perform biopsy. In many cases it is impossible to perform biopsy of solid tumors grown in deep tissues. Cell-free nucleic acids (cfNAs) offer an alternative option. The presence of cfNAs in blood was described in 1948. However, cfNAs such as DNA, mRNA and microRNAs (miRNAs) were not recognized as potential disease biomarkers until recently because of the rapid advance of sequencing technologies^2,3,4. The apoptosis and necrosis of tumor tissues can lead to release of cell-free DNAs (cfDNAs) into the circulating system⁵; these cfDNAs contain crucial genetic and epigenetic information for early diagnosis if sensitive and accurate methods can be developed.Human hepatocellular cancer, one of the most lethal cancers, is characterized by progressive accumulation of epigenetic changes⁶, among which hypermethylation of cancer-associated DNA offers distinct markers for diagnosis. DNA methylation patterns could change throughout the cancer development stages. If the same DNA methylation changes could be monitored in cfDNA released by tumor one could trace the emergence of the cancer, monitor the progression, and predict effects of treatments. Despite these advantages, current cfDNA detection is significantly hampered by the lack of sensitivity because only a very small amount of cfDNA could be obtained from plasma and serum. cfDNA is also heavily fragmented (between 200∼400 bp), adding additional challenges.Faced with these challenges, Wen et al.⁷ invent methylated CpG tandems amplification and sequencing (MCTA-Seq), a method that takes advantage of the fact that CpG tandems are highly enriched in the CpG island-containing promoters of human genome. These CpGs are typically unmethylated but tend to gain hypermethylation in hepatocellular carcinoma (HCC)⁶. The cfDNAs released into circulation carry the same hypermethylation patterns, thereby providing accurate information of the presence of HCC in patients. In their new method, cfDNA is treated with bisulfite, during which non-methylated C (cytosine) is converted to U (uracil) while methylated C remains unaffected. They then use a pair of primers to specifically amplify DNA loci that contain hypermethylated CGCGCGG, a sequence frequently presented in CpG islands and tend to be methylated in cancer tissues. The focus on the CGCGCGG-containing loci may miss other potential markers; however, it offers the sensitivity required for methylation detection in cfDNA. Validation data of MCTA-Seq shows that it is highly reproducible and sensitive, with the detection limit down to as low as 7.5 pg (∼2.5 haploid genome equivalents). Existing biomarkers that are frequently hypermethylated in human cancers⁸, such as VIM, SEPT9, NDRG2 and RASSF1⁸, could be detected with high sensitivity by using MCTA-Seq. The method, although limited by the requirement of the CGCGCGG sequence content, is genome-wide and offers sufficient information about CpG island methylation changes in HCC.Wen et al. applied the new method to detect tumor-specific CGI methylation with plasma samples from HCC patients, cirrhosis patients, and normal individuals. Two types of biomarkers have been identified for early stage HCC diagnosis (Figure 1). Type I markers possess significantly higher methylated CGIs than cancer-free individuals. Type II markers are tissue-specifically methylated CGIs, which tend to be restricted to liver cells under normal circumstances but are released into the blood when malignance occurs. Type II markers dominate in the cfDNA at early stage of HCCs, making them sensitive signs of tumor emergence.Open in a separate windowFigure 1Hypermethylated cfDNA released into the blood can be detected with a new method. Cell-free DNA-containing hypermethylated CpG islands (mCGIs) circulating in the blood of heptocellular carcinoma patients can be detected for early diagnosis. These marker DNAs are released by either tumor cells undergoing apoptosis or necrosis (type I) or adjacent non-cancerous cells affected by tumor growth (type II).The new method and the use of marker combination shown by Wen et al. provide a new strategy for DNA methylation detection from cfDNA. It may have widely applicable potential not only in HCC but also a cohort of other cancer types.     

Tumor volume estimation by the percentage carcinoma method in uterine cervix carcinoma

OBJECTIVE: To assess the capacity of the percentage carcinoma method to predict tumor volume in cervical carcinoma and generate a mathematical equation for calculation of tumor volume. STUDY DESIGN: Thirteen radical hysterectomy specimens were studied. The actual tumor volume was assessed by stereology. A factor was generated by the formula tumor volume = factor x percentage carcinoma x number of blocks. The percentage carcinoma was calculated by the grid method. Then tumor volume was estimated by the same formula. The relationship between actual and estimated tumor volumes was analyzed by Spearman's correlation. RESULTS: Correlation of the tumor volumes assessed by the two methods was excellent (r = .945) and statistically significant (P = .01). CONCLUSION: Percentage carcinoma assessed by the grid ratio method is highly predictive of tumor volume, but care must be taken not to overstate the importance of our results due to the small number of patients. The prediction of outcome in cervical carcinoma by means of percentage carcinoma should be evaluated in large clinical studies.     

Comparative diagnostic efficacy of serum squamous cell carcinoma antigen in hepatocellular carcinoma

ABSTRACT: Hepatocellular carcinoma (HCC) is a common liver malignancy in Nigeria. Hepatitis B and C viruses, alcohol and Aflatoxin B are among the various aetiology. More work needs to be done in the search for markers that will aid early detection of this condition as it is uniformly fatal once advanced. Alphafetoprotein (AFP) remains the most widely used tumour marker of HCC detection in spite of its known shortcomings. The objective of this study was to determine the efficacy of serum squamous cell carcinoma antigen (SCCA) , in comparison to alphafetoprotein in the detection of HCC. METHOD: Sixty patients with HCC and thirty apparently healthy controls attending the Medical Outpatient Department(MOPD) of the University College Hospital Ibadan(UCH) Nigeria were selected for the study. Questionnaire was used to collect clinical data while AFP, SCCA levels,serum HBsAg and anti-HCV were determined using ELISA method- ( Diagnostic Automation Inc. Canada),Abdominal ultrasound scan was also done. Result:Thirty one(51.7%) out of 60 selected cases were positive for HBsAg while six(20%) out of 30 controls were positive for HBsAg(p= 0.004) .Out of the 60 cases selected for this study only 2 (3.3.%) cases were positive for hepatitis C virus, while only 1(3.3%) out of 30 control was positive for hepatitis C virus(p= 0.74). The mean AFP value for cases with HCC was 393.21ng/ml +/-386.97 compared to the control group which was 5.60 +/- 13.03 ng/ml (P value 0.001).The mean SCCA level was 0.64 +/- 0.56ng/ml and 0.71+/-0.65ng/ml for cases and controls respectively (p=0.631) CONCLUSION: Alphafetoprotein remains a good tumour marker for the diagnosis of HCC. Serum squamous cell carcinoma antigen(SCCA) has no discriminatory power and may not be useful as a tumour marker for Nigerians with hepatocellular carcinoma.     

Epithelial carcinoma in Anabas testudineus

Histological examination of a skin tumour from Anabas testudineus indicated its carcinogenic nature. Two types of bacteria were isolated from the tumour and adjacent tissue.     

Muscarinic signaling in carcinoma cells

We previously reported that activation of M(3) muscarinic acetylcholine receptors (mAChR) generates anti-proliferative signals and stimulates cadherin-mediated adhesion in the SCC-9 small cell lung carcinoma (SCLC) cell line. The current study was undertaken to determine the frequency of functional mAChR expression among different SCLC cell lines, and to test the ability of mAChR to generate anti-proliferative signals in different SCLC cell lines. The potential role of Rac1 in SCLC cell-cell adhesion was also investigated. Exposure to the mAChR agonist carbachol induces robust Ca(2+) mobilization (indicated by intracellular fluorescence of the Ca(2+)-binding dye Indo-1) in three SCLC cell lines (SCC-9, SCC-15, and NCI-H146), modest Ca(2+) mobilization in one SCLC cell line (NCI-H209), and no detectable Ca(2+) mobilization in two SCLC cell lines (SCC-18 and NCI-H82). The M(3) mAChR-selective antagonist 4-diphenylacetoxy-N-methylpiperidine methiodide inhibits Ca(2+) mobilization in all SCLC cell lines responding to carbachol. Incubation with carbachol for four hours significantly inhibits [3H]thymidine uptake in three of the four SCLC cell lines expressing functional mAChR (SCC-9, SCC-15, and NCI-H146 cells), but does not significantly alter [3H]thymidine uptake in the other SCLC cell lines examined. These results indicate that SCLC cell lines often express functional mAChR which elicit anti-proliferative signals when activated. To investigate the role of Rac1 in SCLC adhesion, SCC-9 cells were transiently transfected with cDNA constructs coding for Rac1, constitutively active Rac1(Val-12), or dominant negative Rac1(Asn-17) tagged to green fluorescent protein (GFP). SCC-9 cells expressing GFP-tagged constitutively active Rac1(Val-12) exhibit increased cell-cell adhesion in comparison to cells expressing GFP-Rac1 or GFP-Rac1(Asn-17). Constitutively active GFP-Rac1(Val-12), but not GFP-Rac1 or GFP-Rac1(Asn-17), accumulates at cell-cell junctions in SCC-9 cells. These results indicate that activated Rac1 increases SCLC cell-cell adhesion, consistent with the possibility that Rac1 activation contributes to increased SCLC cell-cell adhesion induced by mAChR stimulation. These findings indicate that activation of mAChR may play a significant role in regulating the proliferation and adhesion of SCLC cells. The demonstration by other investigators that acetylcholine is expressed by a variety of cells in the airways supports the possibility that acetylcholine may activate mAChR expressed by SCLC cells in primary tumors.     

Fractal dimension in endometrial carcinoma

OBJECTIVE: To mathematically assess in a pilot study, endometrial glandular margin irregularity in simple hyperplasia, complex atypical hyperplasia and well-differentiated endometrial carcinoma with the help of box counting of fractal dimension and to discriminate these lesions on the basis of box counting of fractal dimension of the gland. STUDY DESIGN: Ten cases each of endometrial simple hyperplasia (without atypia), complex hyperplasia with atypia and endometrial carcinoma (well-differentiated, endometrioid) were assessed in the study. Five fields at 20 x magnification from each case were randomly selected, and the glands were outlined with the help of a pointer. Using the box counting method, the fractal dimension of each case was measured. RESULTS: Mean fractal dimension in simple hyperplasia, complex atypical hyperplasia and endometrial carcinoma was, 0.899 +/- 0.13, 0.932 +/- 0.042 and 0.939 +/- 0.02, respectively. Statistical analysis showed that the fractal dimension of glands of simple hyperplasia were significantly different from that of complex atypical hyperplasia and endometrial carcinoma (P = .041 and .013, respectively, ANOVA). However, there was no significant difference in fractal dimension between glands of complex hyperplasia and of endometrial carcinoma (P = .659, ANOVA). CONCLUSION: This study provides mathematical (objective) assessment of the measurement of glandular margin irregularities in simple hyperplasia, complex atypical hyperplasia and endometrial carcinoma. Fractal dimension of gland margin may have diagnostic potential in the future.     

Haptoglobin groups in ovarian carcinoma

Haptoglobin groups were determined in 182 patients with primary ovarian carcinoma. Previously reported associations could not be confirmed. A significant excess of HP2-1 was observed among patients with a family history of cancer.